Faron Pharmaceuticals Oy

AIM:FARN Stock Report

Market Cap: UK£104.4m

Faron Pharmaceuticals Oy Past Earnings Performance

Past criteria checks 0/6

Faron Pharmaceuticals Oy's earnings have been declining at an average annual rate of -17.7%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 95.6% per year.

Key information

-17.7%

Earnings growth rate

-2.5%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate-95.6%
Return on equityn/a
Net Marginn/a
Next Earnings Update27 Aug 2024

Recent past performance updates

Recent updates

Faron Pharmaceuticals Oy's (LON:FARN) Intrinsic Value Is Potentially 74% Above Its Share Price

Aug 02
Faron Pharmaceuticals Oy's (LON:FARN) Intrinsic Value Is Potentially 74% Above Its Share Price

Do Institutions Own Faron Pharmaceuticals Oy (LON:FARN) Shares?

Mar 05
Do Institutions Own Faron Pharmaceuticals Oy (LON:FARN) Shares?

What Type Of Shareholders Make Up Faron Pharmaceuticals Oy's (LON:FARN) Share Registry?

Nov 20
What Type Of Shareholders Make Up Faron Pharmaceuticals Oy's (LON:FARN) Share Registry?

Revenue & Expenses Breakdown
Beta

How Faron Pharmaceuticals Oy makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

AIM:FARN Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-31920
30 Sep 230-30919
30 Jun 230-29819
31 Mar 230-29820
31 Dec 220-29821
30 Sep 220-26920
30 Jun 220-241118
31 Mar 220-221018
31 Dec 210-211017
30 Sep 210-21817
30 Jun 210-20517
31 Mar 210-19516
31 Dec 200-17514
30 Sep 200-16412
30 Jun 200-14411
31 Mar 200-14411
31 Dec 190-13310
30 Sep 190-13310
30 Jun 190-12310
31 Mar 190-16313
31 Dec 180-20416
30 Sep 181-24421
30 Jun 181-28425
31 Mar 181-25322
31 Dec 171-21319
30 Sep 172-17315
30 Jun 172-14311
31 Mar 172-12310
31 Dec 162-1029
30 Sep 160-938
30 Jun 160-736
31 Mar 161-735
31 Dec 151-634
30 Sep 151-523
30 Jun 151-312
31 Mar 151-212
31 Dec 141-101
31 Dec 130-202

Quality Earnings: FARN is currently unprofitable.

Growing Profit Margin: FARN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: FARN is unprofitable, and losses have increased over the past 5 years at a rate of 17.7% per year.

Accelerating Growth: Unable to compare FARN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FARN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).


Return on Equity

High ROE: FARN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.